Co-magaldrox (Aluminium and Magnesium Hydroxide)
Brand names: Mucogel
Co-magaldrox is an antacid combining aluminium hydroxide and magnesium hydroxide, used for the symptomatic relief of dyspepsia, heartburn and acid-related upper gastrointestinal discomfort.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
The constituent hydroxides neutralise gastric acid, raising intragastric pH; pairing aluminium and magnesium salts balances their opposing effects on bowel transit.
Prescribing in practice
- Use with caution in renal impairment, where aluminium and magnesium can accumulate and cause toxicity, and avoid in hypophosphataemia.
- Separate dosing from other oral medicines because antacids reduce the absorption of many drugs, including certain antibiotics, bisphosphonates and iron.
- Be aware the preparation contains sodium and may cause altered bowel habit, with magnesium tending to loosen and aluminium to constipate.
Monitoring
Routine monitoring is not generally required for short-term use, but consider renal function and electrolytes in patients with renal impairment or prolonged use.
Counselling the patient
- Take after meals and at bedtime, or when symptoms occur.
- Leave a gap between this and your other medicines.
- See a doctor if symptoms persist or worsen.
Evidence & guidelines
Antacid efficacy for symptomatic acid-related dyspepsia is well established and reflected in current prescribing references and the SPC.
Reference: SPC Mucogel; NICE CG17 Dyspepsia; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021